eXoZymes, Inc. (EXOZ) - Total Liabilities
Based on the latest financial reports, eXoZymes, Inc. (EXOZ) has total liabilities worth $2.34 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EXOZ cash generation efficiency to assess how effectively this company generates cash.
eXoZymes, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how eXoZymes, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See eXoZymes, Inc. (EXOZ) shareholders funds for net asset value and shareholders' equity analysis.
eXoZymes, Inc. Competitors by Total Liabilities
The table below lists competitors of eXoZymes, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Envirosuite Ltd
AU:EVS
|
Australia | AU$31.96 Million |
|
APCB Inc
TW:6108
|
Taiwan | NT$3.25 Billion |
|
ESTec Corporation
KQ:069510
|
Korea | ₩127.62 Billion |
|
Les Docks des Pétroles d'Ambès -SA
PA:DPAM
|
France | €9.93 Million |
|
Q.S.I Co. LTD
KQ:066310
|
Korea | ₩4.82 Billion |
|
ESTsoft Corp
KQ:047560
|
Korea | ₩120.13 Billion |
|
Strix Group Plc
F:SG9
|
Germany | €131.53 Million |
|
Seanergy Maritime Holdings Corp
F:RHSR
|
Germany | €291.90 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down eXoZymes, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EXOZ company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how eXoZymes, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for eXoZymes, Inc. (2021–2024)
The table below shows the annual total liabilities of eXoZymes, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.61 Million | -33.71% |
| 2023-12-31 | $3.94 Million | +200.26% |
| 2022-12-31 | $1.31 Million | +14.28% |
| 2021-12-31 | $1.15 Million | -- |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, Califor… Read more